Dr. Gatti-Mays is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Stefanie Spielman Comprehensive Breast Center
1145 Olentangy River Road
Columbus, OH 43212Phone+1 614-293-0066Fax+1 614-293-7264- Is this information wrong?
Summary
- Dr. Margaret Gatti-Mays is an Associate Professor of Medical Oncology at The Ohio State University (Columbus, OH). She is board certified in medical oncology with a primary focus in breast cancer and immuno-oncology. Her research is based in the clinic and focuses on tumor immunology and the development of novel approaches including cancer vaccines, cytokines, antibodies or immune modulators.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2015 - 2017
MedStar Health/Georgetown University HospitalChief Residency, Internal Medicine, 2014 - 2015- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2011 - 2014
Georgetown University School of MedicineClass of 2011
Rollins School of Public Health, Emory UniversityMPH, Epidemiology , 2005 - 2007
Certifications & Licensure
OH State Medical License 2020 - 2026
MD State Medical License 2017 - 2020
DC State Medical License 2011 - 2020
VA State Medical License 2013 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow ACP, 2019
Clinical Trials
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) Start of enrollment: 2021 May 04
- Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer Start of enrollment: 2024 Mar 01
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer Start of enrollment: 2019 Nov 12
Publications & Presentations
PubMed
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christophe...> ;Nature Communications. 2024 Mar 27
- 1 citationsComparing the rate of immunotherapy treatment change due to toxicity by sex.Chua, K., Liu, H., Schneider, B., Sterling, J., Singer, E., Kronstedt, S., Kaldany, A., Srivastava, A., Tarhini, A., Gatti-Mays, M., Gaughan, E., Hu-Lieskovan, S., Alj...> ;Cancer Reports. 2024 Feb 1
- Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer-Still Haven't Found What We're Looking For.Quiroga, D., Gatti-Mays, M.> ;JAMA Oncology. 2024 Feb 1
- Join now to see all
Press Mentions
A Unique Approach for Treating Hormone Receptor Positive Breast CancerApril 21st, 2023- As Breast Cancer Awareness Month Ends, Ohio State Doctors Push Early DetectionOctober 31st, 2022
- What You Need to Know About Metastatic Breast Cancer, According to an Oncology Expert - ExclusiveAugust 10th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
Ohio State University Wexner Medical CenterColumbus, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
